LJPP Stock Overview
La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases.
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 4/6 |
Past Performance | 3/6 |
Financial Health | 0/6 |
Dividends | 0/6 |
Rewards
Risk Analysis
La Jolla Pharmaceutical Company Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$6.07 |
52 Week High | US$6.11 |
52 Week Low | US$2.94 |
Beta | 2.41 |
1 Month Change | 1.40% |
3 Month Change | 73.44% |
1 Year Change | 93.75% |
3 Year Change | -33.65% |
5 Year Change | -75.48% |
Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Shareholder Returns
LJPP | DE Biotechs | DE Market | |
---|---|---|---|
7D | 1.6% | 2.8% | -0.03% |
1Y | 93.7% | 38.7% | 5.5% |
Rentabilidad frente al sector: LJPP superó al sector German Biotechs , que obtuvo un rendimiento del -23.1% el año pasado.
Rentabilidad vs. Mercado: LJPP superó al mercado German, que obtuvo un rendimiento del 5.9% el año pasado.
Price Volatility
LJPP volatility | |
---|---|
LJPP Average Weekly Movement | 24.2% |
Biotechs Industry Average Movement | 5.4% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.1% |
10% least volatile stocks in DE Market | 2.4% |
Precio estable de las acciones: LJPPha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: LJPPLa volatilidad semanal ha pasado de 14% a 24% en el último año.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1989 | 61 | Larry Edwards | https://www.lajollapharmaceutical.com |
La Jolla Pharmaceutical Company Fundamentals Summary
LJPP fundamental statistics | |
---|---|
Market cap | €155.85m |
Earnings (TTM) | €3.99m |
Revenue (TTM) | €46.72m |
39.1x
P/E Ratio3.3x
P/S RatioIs LJPP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
LJPP income statement (TTM) | |
---|---|
Revenue | US$46.49m |
Cost of Revenue | US$8.87m |
Gross Profit | US$37.62m |
Other Expenses | US$33.65m |
Earnings | US$3.97m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | 0.16 |
Gross Margin | 80.92% |
Net Profit Margin | 8.54% |
Debt/Equity Ratio | -179.3% |
How did LJPP perform over the long term?
See historical performance and comparison